Immunic, inc. reports year end 2023 financial results and provides corporate update
– significantly strengthened balance sheet in january 2024 with execution of three-tranche private placement of up to $240 million, extending cash runway into the third quarter of 2025 based on initial $80 million tranche – – evidence for neuroprotective activity of vidofludimus calcium from phase 2 calliper interim analysis, consistent across the entire progressive multiple sclerosis population and all subtypes; top-line calliper data expected in april 2025 – – phase 3 ensure program in relapsing multiple sclerosis ongoing – – expanded vidofludimus calcium patent portfolio with additional new patents granted; exclusivity protection expected into 2041 in the united states, unless extended further – – webcast to be held today, february 22, 2024, at 8:00 am et – new york , feb. 22, 2024 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended december 31, 2023, and provided a corporate update. "immunic made remarkable progress throughout 2023, and these achievements were punctuated by the successful three-tranche private placement of up to $240 million, which we announced last month.
IMUX Ratings Summary
IMUX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission